Oral Semaglutide Investigated for Pharmacokinetic Interactions with Ethinylestradiol and Levonorgestrel in Postmenopausal Women

Treatments for Type 2 Diabetes and obesity often involve oral medications. Oral semaglutide, a GLP-1 receptor agonist, is known to slow gastric emptying, a mechanism that can significantly alter the absorption of co-administered oral drugs. This interaction is particularly critical for medications with narrow therapeutic windows or those requiring precise systemic exposure, such as oral contraceptives. Ensuring there are no significant pharmacokinetic interactions between oral semaglutide and common medications like ethinylestradiol and levonorgestrel is paramount for patient safety and maintaining contraceptive efficacy, especially in populations where both medications might be prescribed concurrently.

This was a Phase 1 clinical trial conducted in Europe, designed to investigate potential drug-drug interactions. The study focused on the pharmacokinetics (PK) of ethinylestradiol and levonorgestrel, which are active components of an oral contraceptive combination drug. The trial enrolled healthy postmenopausal females. The primary objective was to determine the influence of co-administered oral semaglutide on the systemic exposure of these contraceptive hormones. The study design likely involved administering the oral contraceptive alone and then in combination with oral semaglutide to assess any changes in key pharmacokinetic parameters such as AUC (area under the curve) and Cmax (maximum plasma concentration) for both hormones.

Results from this specific trial were not provided in the given research record. Therefore, specific findings regarding the pharmacokinetic interactions between oral semaglutide and ethinylestradiol or levonorgestrel cannot be reported. The study's aim was to quantify any changes in systemic exposure (AUC) and peak concentration (Cmax) of the contraceptive hormones when co-administered with oral semaglutide, which is crucial for understanding potential drug-drug interactions. Without the data, it is not possible to determine if oral semaglutide significantly altered the absorption or metabolism of the oral contraceptive components, nor can any specific percentages, p-values, or fold-changes be cited.